Company / Cash & Equivalents
CUMBERLAND PHARMACEUTICALS INC Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$11.4M
FY2025
5-year range
$11.4M / $27.0M
FY2021-FY2025
Trend
-36.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has declined for 4 consecutive years, from $27M in FY2021 to $11M in FY2025.
Based on SEC 10-K filings.
$11M in FY2025 with a 5-year CAGR of -14.3%.
Declined from $18M to $11M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -16.6%
- 5-Year CAGR
- -14.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- CUMBERLAND PHARMACEUTICALS INC's cash & equivalents has declined for 4 consecutive years.
- 5-year CAGR of -14.3%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 36.3% year-over-year.
- Peak cash & equivalents was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $11.4M | -36.3% |
| FY2024 | $18.0M | -2.0% |
| FY2023 | $18.3M | -7.3% |
| FY2022 | $19.8M | -26.9% |
| FY2021 | $27.0M | +9.2% |
| FY2020 | $24.8M | -12.3% |
| FY2019 | $28.2M | -37.9% |
| FY2018 | $45.4M | +18.9% |
| FY2017 | $38.2M | -4.2% |
| FY2016 | $39.9M | -2.5% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026